Billion dollar science and technology company Dowpharma, a business unit of The Dow Chemical company, has announced new capabilities in catalytic asymmetric hydroformylation (AHF) of olefins for applications in the development and manufacture of pharmaceutical intermediates.
AHF combines the creation of a chiral centre with the introduction of versatile aldehyde functionality, the company outlined this week. For Dowpharma, the range of benefits from this new technology includes a more efficient and 'cost-effective manufacturing system' that produces less waste, it shortens the route to drug development 'by capitalising on AHF's versatile aldehyde functionality' and avoids inefficient drug separation technology.
"Dowpharma has established a leading capability in asymmetric hydroformylation," said Nick Hyde, business director, Dowpharma. "Within the pharmaceutical sector, this has been an under-exploited technology with untapped opportunities for commercial applications. We anticipate a high degree of applicability for the synthesis of chiral building blocks and customer-specific intermediates for APIs."
The challenge in AHF reactions is to achieve efficient catalysis with control of regioselectivity as well as enantioselectivity. Identifying the best match of substrate to catalyst requires access to a broad catalyst library, states the company this week. In addition, claims Dowpharma, customers can gain access to Dowpharma's broad catalyst library through a 'comprehensive screening service backed by specialised process chemistry, analytical chemistry and engineering expertise in implementing AHF technology.'
Dr. Greg Whiteker of The Dow Chemical Company will present new detailed results using the technology at the upcoming Chiral Europe 2003 in London from 12 - 14 May.